関連する実験動画
Updated: May 15, 2026

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
慢性疾患における抗炎症療法:課題と機会
Ira Tabas1, Christopher K Glass
1Department of Medicine, Columbia University, New York, NY 10032, USA. iat1@columbia.edu
まとめ
慢性炎症性疾患である動脈硬化症やアルツハイマー病などの治療は困難です. 炎症シグナル伝達と薬物開発に関する新しい研究は,有望な治療戦略を提供します.
科学分野:
- バイオメディカル・リサーチ
- 翻訳医学は翻訳医学である.
- 免疫学 免疫学とは
背景:
- 動脈硬化症,2型糖尿病,アルツハイマー病などの慢性疾患は,重要な炎症成分を共有しています.
- これらの状態で炎症を誘発する要因を特定し,除去することは,しばしば困難です.
- 炎症反応をターゲットにすることは,限界にもかかわらず,治療の機会を提示します.
研究 の 目的:
- 慢性疾患における炎症反応を標的とした治療的介入の可能性を調査する.
- 複雑な慢性疾患に対する抗炎症療法における課題と機会を見直す.
- 炎症シグナル伝達と解消経路の理解における新たな進歩の約束を強調する.
主な方法:
- 炎症シグナル伝達経路に関する現在の理解のレビュー.
- 慢性疾患の病理生理学における炎症の役割の分析.
- 抗炎症薬の開発の限界と潜在的な利点の検討.
主要な成果:
- 炎症反応は生存に不可欠であり,補償経路による抗炎症薬の開発を複雑にする.
- 既存の抗炎症療法には,トリガーが不明または取り除けない慢性疾患の制限があります.
- 炎症信号伝達と解消経路の理解における進歩は極めて重要です.
結論:
- 課題があるにもかかわらず,炎症経路をターゲットにすることは,慢性疾患における治療革新の重要な分野です.
- 炎症と解消経路に焦点を当てた新薬の開発は,翻訳的生物医学研究にとって有望である.
- 炎症信号のより深い理解は,広範囲にわたる慢性疾患の治療戦略を改善するために不可欠です.
さらに関連する動画
関連する概念動画
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

